WO2003037361A3 - Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis - Google Patents

Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis Download PDF

Info

Publication number
WO2003037361A3
WO2003037361A3 PCT/DK2002/000727 DK0200727W WO03037361A3 WO 2003037361 A3 WO2003037361 A3 WO 2003037361A3 DK 0200727 W DK0200727 W DK 0200727W WO 03037361 A3 WO03037361 A3 WO 03037361A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue factor
apoptosis
treatment
agonist
conditions related
Prior art date
Application number
PCT/DK2002/000727
Other languages
French (fr)
Other versions
WO2003037361A2 (en
Inventor
Brit Binow Soerensen
Lars Christian Petersen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Priority to AU2002336920A priority Critical patent/AU2002336920A1/en
Priority to JP2003539704A priority patent/JP2005507008A/en
Priority to EP02772090A priority patent/EP1443956A2/en
Publication of WO2003037361A2 publication Critical patent/WO2003037361A2/en
Publication of WO2003037361A3 publication Critical patent/WO2003037361A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions increased or decreased cell apoptosis is required.
PCT/DK2002/000727 2001-11-02 2002-11-01 Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis WO2003037361A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002336920A AU2002336920A1 (en) 2001-11-02 2002-11-01 Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
JP2003539704A JP2005507008A (en) 2001-11-02 2002-11-01 Use of a tissue factor agonist or tissue factor antagonist for the treatment of symptoms associated with apoptosis
EP02772090A EP1443956A2 (en) 2001-11-02 2002-11-01 Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101628 2001-11-02
DKPA200101628 2001-11-02

Publications (2)

Publication Number Publication Date
WO2003037361A2 WO2003037361A2 (en) 2003-05-08
WO2003037361A3 true WO2003037361A3 (en) 2004-03-25

Family

ID=8160809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000727 WO2003037361A2 (en) 2001-11-02 2002-11-01 Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis

Country Status (4)

Country Link
EP (1) EP1443956A2 (en)
JP (1) JP2005507008A (en)
AU (1) AU2002336920A1 (en)
WO (1) WO2003037361A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1587549A2 (en) * 2003-01-22 2005-10-26 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
WO2009146746A1 (en) * 2008-06-05 2009-12-10 Universite Libre De Bruxelles Use of fxa, fviia, tf, or a combination thereof as anti-apoptotic agents
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
JP6055404B2 (en) 2010-06-15 2016-12-27 ゲンマブ エー／エス Human antibody drug conjugates against tissue factor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005328A1 (en) * 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
WO1994027631A1 (en) * 1993-05-21 1994-12-08 Zymogenetics, Inc. Modified factor vii
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
WO1999003498A1 (en) * 1997-07-18 1999-01-28 Novo Nordisk A/S USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
WO1999016789A1 (en) * 1997-09-30 1999-04-08 Peviva Ab Apoptosis-related compounds and their use
WO2001005353A2 (en) * 1999-07-14 2001-01-25 Novo Nordisk A/S USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
WO2001030333A2 (en) * 1999-10-27 2001-05-03 Sunol Molecular Corporation Tissue factor antagonists and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
WO1994005328A1 (en) * 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
WO1994027631A1 (en) * 1993-05-21 1994-12-08 Zymogenetics, Inc. Modified factor vii
WO1999003498A1 (en) * 1997-07-18 1999-01-28 Novo Nordisk A/S USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
WO1999016789A1 (en) * 1997-09-30 1999-04-08 Peviva Ab Apoptosis-related compounds and their use
WO2001005353A2 (en) * 1999-07-14 2001-01-25 Novo Nordisk A/S USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
WO2001030333A2 (en) * 1999-10-27 2001-05-03 Sunol Molecular Corporation Tissue factor antagonists and methods of use thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CH. WALTHER ET AL: "Ein neuer Fall von Hypoproconvertinämie (Faktor VII-Mangel), zugleich Bericht einer Substitutionsbehandlung während eines stereotaktischen Eingriffes beim Parkinsonsyndrom.", ARCHIV FÜR KLINISCHE MEDIZIN, vol. 215, 1968, pages 161 - 173, XP002902828 *
CURRENT OPINION IN LIPIDOLOGY. UNITED STATES OCT 1996, vol. 7, no. 5, October 1996 (1996-10-01), pages 330 - 335, ISSN: 0957-9672 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; October 1996 (1996-10-01), LIBBY P ET AL: "Macrophages and atherosclerotic plaque stability.", XP002902830, Database accession no. NLM8937525 *
GREENO E W ET AL: "Apoptosis is associated with increased cell surface tissue factor procoagulant activity.", LABORATORY INVESTIGATION, vol. 75, no. 2, August 1996 (1996-08-01), pages 281 - 289, XP002902825, ISSN: 0023-6837 *
MARK M. KOCKX ET AL: "Decreased apoptosis and tissue factor expression after lipid lowering.", CIRCULATION, vol. 102, no. 13, 2000, pages e99, XP002902829 *
MICHAEL E. BROMBERG ET AL: "Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation", PROC. NATL. ACAD. SCI., vol. 92, August 1995 (1995-08-01), pages 8205 - 8209, XP002244648 *
RINSHO BYORI, vol. 45, no. 7, July 1997 (1997-07-01), pages 614 - 620, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uid...> [retrieved on 20030211] *
TAKEYA H ET AL: "Thrombosis and apoptosis", DATABASE PUB MED / NCBI, PMID 9256006, pages 1, XP002902826 *
YASUSADA KAWADA ET AL: "Successful treatment of an infant with fulminant hepatitis by factor VII concentrate.", JAPANESE JOURNAL OF CLINICAL HEMATOLOGY, vol. 30, no. 11, 1989, pages 1982 - 1986, XP002902827 *

Also Published As

Publication number Publication date
AU2002336920A1 (en) 2003-05-12
EP1443956A2 (en) 2004-08-11
JP2005507008A (en) 2005-03-10
WO2003037361A2 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
AU2002352443A1 (en) Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
HK1079426A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
HK1121463A1 (en) Treatment of tnf alpha related disorders tnf
IL160295A0 (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidines structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson&#39;s disease
AU2003216586A8 (en) Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
SI1627639T1 (en) Use of COX-2 inhibitors for the treatment of affective disorders
HRP20030874A2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
IS6967A (en) New cyano-linked dihydropyrimidine compounds and their use in the treatment of diseases
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
HUP0303306A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
WO2003037361A3 (en) Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
IL147294A0 (en) USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGUATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
GB0128674D0 (en) Treatment of sleep disorders and the like
AU2003287915A8 (en) Use of factor vii polypeptides for preventing formation of inhibitors to blood coagulation factor viii and ix
EP1539100A4 (en) Composition and methods for the treatment of skin disorders
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
AU2002240745A1 (en) Diagnosis and treatment of blood disorders
AU2003252185A8 (en) Topical composition for the treatment of scar tissue
AU2003208368A1 (en) Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases
AU2003216954A1 (en) Treatment of dependence and dependence related withdrawal symptoms
AU2002339680A1 (en) Agonists and antagonists of bromix for the treatment of metabolic disorders
AU2002315314A1 (en) Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases
AU2002952346A0 (en) Diagnosis and treatment of disorders
AU2003294697A1 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002772090

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003539704

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002772090

Country of ref document: EP